Current Research On CBD:
1.) Xiong W, Cui T, Cheng K, et al. Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. The Journal of Experimental Medicine. 2012;209(6):1121-1134. doi:10.1084/jem.20120242.
2.) Neelakantan, H., Tallarida, R.J., Reichenbach, Z.W., Tuma, R.F., Ward, S.J. and Walker, E.A., 2015. Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Behavioural pharmacology, 26(3), pp.304-314.Schizophrenia Research. 162 (1–3): 153–61.
3.) Fitzcharles, M. A., Baerwald, C., Ablin, J., & Häuser, W. (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis). Der Schmerz, 30(1), 47-61.
https://www-ncbi-nlm-nih-gov.uml.idm.oclc.org/pubmed/26767993
4.) Antonio Waldo Zuardi, Jose Alexandre S. Crippa, Jaime E.C. Hallak, Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Philip K. McGuire and Francisco Silveira Guimaraes. Current Pharmaceutical Design (2012) 18: 5131. Schizophrenia Research. 162 (1–3): 153–61.
5.) Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR (January 2010). “Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors”. British Journal of Pharmacology. 159 (1): 122–8. doi:10.1111/j.1476-5381.2009.00521.x.Schizophrenia Research. 162 (1–3): 153–61.
6.) Hurd YL, Yoon M, Manini AF, et al. Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics. 2015;12(4):807-815. doi:10.1007/s13311-015-0373-7.Schizophrenia Research. 162 (1–3): 153–61.
7.) Lehmann, C., Fisher, N.B., Tugwell, B., Szczesniak, A., Kelly, M. and Zhou, J., 2016. Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. Clinical hemorheology and microcirculation, 64(4), pp.655-662.Schizophrenia Research. 162 (1–3): 153–61.
8.) Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. Neuropsychopharmacology. 2011;36(6):1219-1226. doi:10.1038/npp.2011.6.
9.) Babson, K. A., Sottile, J., & Morabito, D. (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current psychiatry reports, 19(4), 23.
Iseger TA, Bossong MG (March 2015). “A systematic review of the antipsychotic properties of cannabidiol in humans”. Schizophrenia Research. 162 (1–3): 153–61.
Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K, Fujiwara M (May 2005). “Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism”. Stroke. 36 (5): 1077–82. doi:10.1161/01.STR.0000163083.59201.34 Schizophrenia Research. 162 (1–3): 153–61.
https://www.ncbi.nlm.nih.gov/pubmed/15845890
Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M (March 2007). “Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance”. Neuropharmacology. 52 (4): 1079–87. doi:10.1016/j.neuropharm.2006.11.005 Schizophrenia Research. 162 (1–3): 153–61.
Campos AC, Guimarães FS (August 2008). “Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats”. Psychopharmacology. 199 (2): 223–30. doi:10.1007/s00213-008-1168-x.Schizophrenia Research. 162 (1–3): 153–61.
Perucca E (December 2017). “Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?”. J Epilepsy Res. 7 (2): 61–76. doi:10.14581/jer.17012.
Scotter, E. L., Abood, M. E. and Glass, M. (2010), The endocannabinoid system as a target for the treatment of neurodegenerative disease. British Journal of Pharmacology, 160: 480-498. doi:10.1111/j.1476-5381.2010.00735.xSchizophrenia Research. 162 (1–3): 153–61.
https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1476-5381.2010.00735.x
Esposito, G., De Filippis, D., Carnuccio, R. et al. J Mol Med (2006) 84: 253. https://doi.org/10.1007/s00109-005-0025-1Schizophrenia Research. 162 (1–3): 153–61.
https://link.springer.com/article/10.1007%2Fs00109-005-0025-1
Giacoppo, S., Pollastro, F., Grassi, G., Bramanti, P. and Mazzon, E., 2017. Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis. Fitoterapia, 116, pp.77-84 Schizophrenia Research. 162 (1–3): 153–61.
Guindon, J. and Hohmann, A. G. (2011), The endocannabinoid system and cancer: therapeutic implication. British Journal of Pharmacology, 163: 1447-1463. doi:10.1111/j.1476-5381.2011.01327.xSchizophrenia Research. 162 (1–3): 153–61.
http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2011.01327.x/full
McAllister SD, Soroceanu L, Desprez P-Y. The antitumor activity of plant-derived non-psychoactive cannabinoids. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2015;10(2):255-267. doi:10.1007/s11481-015-9608-y.Schizophrenia Research. 162 (1–3): 153–61.